rewrite this title Could Intuitive Surgical Be a Trillion-Dollar Company? – Nanalyze

Of the 313 million surgical procedures undertaken worldwide each year, only 6% occur in the poorest countries, where over a third of the world’s population lives. That factoid is from a great report by The Lancet which postulates that democratized surgical availability should result in 5,000 surgeries for every 100,000 people annually. That’s about 425 million surgeries a year minimum with adequate coverage. At $10,000 a pop, that’s about a $4 trillion market. Why not build a bunch of robots to perform these surgeries and harvest dollars alongside organs?

TAM vs. SAM

Let’s start with a very important concept – total addressable market or TAM. While the global TAM for surgical procedures may be massive, the number of surgeries that can be performed by robotic solutions is much smaller. Robots excel in elective, precision-driven, minimally invasive soft-tissue cases which represent about 5% of surgical volume – roughly 20 million procedures. So, the TAM for robotic surgeries sits at only 20 million annual procedures.

Now, how many of these procedures can be performed by the leading robotic surgical platform out there – Intuitive Surgical $ISRG? About nine million procedures annually, and that’s called a serviceable addressable market or SAM. In 2025, ISRG completed about 3 million procedures so they’re currently capturing about 30% of the market they could be capturing. That means there’s plenty of room to grow, but we also need to consider the competition which is slowly encroaching on their space.

Today, we want to try and answer three questions:

Given the above assumptions, how much growth does ISRG have left, assuming their SAM doesn’t expand while considering competitive threats?

What would it take for them to address the additional 11 million procedures they’re not able to address now (TAM minus SAM)?

What’s the possibility that robotic surgery platforms as a whole can move beyond just 5% applicability they enjoy today?

Simply put, could this $160 billion company ever eclipse a trillion-dollar valuation?

Growing Competition

ISRG’s strong gross margins, driven by 84% recurring revenues, coupled with double-digit revenue growth, mean the company is richly priced – a current simple valuation ratio of 14 – but lower than the historical average of 18.

That’s because worldwide da Vinci procedure growth is expected to be in the range of 13% to 15%, down from the 18% growth observed in 2025. (The company provides procedure growth guidance, not revenue growth guidance.) Reasons for the slowdown range from regulatory hurdles in international markets to capacity considerations to competitive pressures. However, the reports of ISRG’s death by emerging competitors are greatly exaggerated.

The closest competitor in terms of procedures performed would be privately-held CMR, which has now treated 45,000 patients in total – about what Intuitive does in five days. CMR is just starting U.S. commercialization following FDA approval late last year. Other companies are rolling out robotic surgery solutions, but they’re targeting a different niche: orthopedic surgery versus soft-tissue surgery. For example, medical device leader Stryker $SYK has completed 2 million knee and hip replacements with their Mako robot, and Zimmer Biomet $ZBH claims their ROSA robot is installed in over 2,000 hospitals for similar use cases. Neither of these companies are direct competitors to Intuitive. A close peer might be Medtronic $MDT with their Hugo robot, but the company doesn’t break out how many procedures have actually been performed. All we know is it was a grand total of roughly 10,000 back in 2024, so they likely still don’t hold a candle to Intuitive’s 3 million annual procedures.

We can safely say that competition isn’t eating Intuitive’s lunch yet, as they still command 60-80% global market share in robot-assisted surgery. But for the company to keep scaling, they need a plan to address new procedures and geographies.

Future Growth Prospects

Intuitive needs to constantly be expanding their offerings to close the gap between their 9 million annual procedure SAM and 20 million annual procedure TAM. The company believes future market share gains will come from three key areas:

Increased cardiac procedures

Adoption by Ambulatory Surgery Centers (ASCs)

Expansion in Europe

In January of this year, Intuitive received FDA approval for a limited amount of cardiac procedures including mitral valve repair and IMA (internal mammary artery) mobilization for cardiac revascularization. This additional approval could open the door for another 160,000 annual procedures. That won’t move the needle much. Regarding ASCs, Intuitive realized these same-day surgery centers often have lower budgets than traditional hospitals, so they’ve started offering used and refurbished da Vinci systems of older models.

Finally, their European expansion appears to be in the early stages, but management claims it grew 21% in 2025. That’s a bit more than the 18% year-over-year growth in overall “Outside U.S.” revenue, but still below the 22% year-over-year growth that U.S. revenues showed in 2025. The 342 total da Vinci systems currently installed in Europe are a drop in the bucket compared to the 9,000 total active da Vinci systems worldwide. We’d expect growth to be a lot stronger off such a small base. Turns out our friends overseas tend to be a bit more price-sensitive due to limited hospital budgets. Expensive surgical robots sell better in ‘Murica thanks to capitalistic healthcare systems. If Intuitive wants to see more growth in Europe, they’ll need to lower their prices and take a hit on margins, or offer used and refurbished devices like they’re doing with ASCs.

Selling additional products to expand their SAM comes down to execution. But can the TAM for robotic surgeries expand to more than 5% of overall surgeries, especially given the advancements we’re seeing in artificial intelligence?

Expanding the TAM

Seems remarkable that only 5% of all surgeries performed worldwide can be performed using robotics platforms. Most surgeons are interested in robotics, yet adoption currently lags. That’s according to a report by Bain that points to “a lack of efficiency due to longer surgery time” as the leading cause why robotics solutions aren’t being adopted. Better outcomes just aren’t enough to surpass that hurdle when faced with “limited clinical evidence and high ongoing and up-front costs.” You also have “many procedures where robots are still in development or face technological obstacles.”

Up-front equipment costs were said to be “the most important consideration when making a purchase” and the third largest barrier to adoption. Being able to offer lower-cost platforms will open doors to expanding the number of procedures. Additional value might be added through “intra-operative device guidance, AI-based planning, and other cutting-edge features” such as 5G-enabled remote surgeries for emerging markets where talent is in short supply. As always, it comes down to the almighty dollar. The 20 million procedure TAM could expand if the cost of these platforms could be reduced. Technology may help address these shortcomings, but ISRG is also expanding into diagnostics as a way to increase their footprint with existing clients.

In other words, why not sell adjacent products since you’re already talking to key decision makers in hospitals?

New Diagnostics Opportunities

Hospitals that can afford expensive robotic surgery platforms have deep pockets. This is where Ion comes into play. Ion is Intuitive’s new endoluminal platform. Endoluminal simply refers to the treatment of the tubes inside a human body, things like blood vessels and intestines. Ion is currently targeting lung biopsy, or the removal of lung cells to test for signs of lung cancer. Since lung cancer is the leading cause of cancer-related death, this opens up another big opportunity for Intuitive. As we’d expect, Ion procedures are growing quickly, up 51% year-over-year in 2025 off a nearly 100,000 procedure base.

Our first question was: “Why did it take so long for Ion to gain momentum?” The platform was released in 2019 but only saw about 1,000 procedures in 2020. Rather than a lack of demand, this steady ramp-up was due to hospitals taking time to go through the necessary hurdles of deploying the new system. Specialists needed to train themselves, and higher-ups needed to approve new budgets to afford the $700,000 device.

We were hoping Intuitive would have some grand plans to roll out other new diagnostic devices to expand their addressable market, but it appears management is more focused on reducing the detection-to-treatment time. After that, the company may look to expand Ion to include treatment options as well as diagnosis. Management also hinted at expanding outside of lung cancer into benign lung disease and COPD detection. The former is very common and not life-threatening, and the latter is a bit more rare, affecting only around 15 million Americans. This hardly seems like a major expansion, but it does provide room for Intuitive to grow in the diagnostic space while remaining a leader in robot-assisted surgery.

The Trillion Dollar Question

If you’re a $160 billion company doing 3.2 million procedures a year which generate $10 billion a year, then all those numbers need to increase by a factor of six to hit the trillion-dollar valuation. So about 20 million procedures a year, which represents the entire total addressable market. Filling the gap between SAM and TAM becomes important. So does keeping the competition at bay. Perhaps their foray into diagnostics can pick up some slack, but we can’t assume that pricing stays the same. If a key barrier to adoption is cost, they’ll eventually need to charge less to increase market share. Less profitable businesses command lower valuations.

Where ISRG can supplement their growth is through adjacent offerings that hospitals with deep pockets might find compelling. In a past visit to Stanford, we looked at how imaging technologies and augmented reality are helping surgeons make better decisions. If ISRG is already speaking to key decision makers, it’s much easier to cross-sell them other technologies that make a surgeon’s life easier.

Ultimately, ISRG needs to use their da Vinci cash cow wisely. With nine billion in cash and investments on hand, and one-third of that amount generated last year from positive operating cash flows, acquiring bolt-on growth or investing heavily in new platforms is what’s needed to keep growth on track should they ever hope to become the world’s largest healthcare company.

Conclusion

Intuitive Surgical has seen revenue growth accelerate for three years now, though this year the forecasted procedure guidance implies a slowdown in growth. Customers cite cost as a major impediment to adoption, and catering to those desires means potentially compressing their margins which makes the business less valuable. It’s a tough position to be in, but technology can make the platform so useful that hospitals can’t afford not to use it. Adjacent platforms and functionality can supplement growth, but ultimately, we need to know that they’re able to capture the additional six million procedures in their SAM and ultimately expand into the additional ten million procedures in their TAM. We’ll check back in a year to see how things are going.